DrugPatentWatch Database Preview
MIRVASO Drug Patent Profile
Email this page to a colleague
When do Mirvaso patents expire, and when can generic versions of Mirvaso launch?
Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-one patent family members in thirty-one countries.
The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mirvaso
A generic version of MIRVASO was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28th, 2003.
Summary for MIRVASO
| International Patents: | 121 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 100 |
| Clinical Trials: | 12 |
| Drug Prices: | Drug price information for MIRVASO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MIRVASO |
| What excipients (inactive ingredients) are in MIRVASO? | MIRVASO excipients list |
| DailyMed Link: | MIRVASO at DailyMed |
Recent Clinical Trials for MIRVASO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | Early Phase 1 |
| Heinrich-Heine University, Duesseldorf | Phase 2 |
| Skin Laser & Surgery Specialists | N/A |
Pharmacology for MIRVASO
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for MIRVASO
Paragraph IV (Patent) Challenges for MIRVASO
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| MIRVASO | GEL;TOPICAL | brimonidine tartrate | 204708 | 2014-12-15 |
US Patents and Regulatory Information for MIRVASO
MIRVASO is protected by twelve US patents.
Patents protecting MIRVASO
Brimonidine gel compositions and methods of use
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Compounds, formulations, and methods for treating or preventing rosacea
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Brimonidine gel composition
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Gel compositions and methods of use
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Compounds, formulations, and methods for ameliorating telangiectasis
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Methods and compositions for treating or preventing erythema
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Methods and compositions for safe and effective treatment of erythema
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Methods and compositions for safe and effective treatment of erythema
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Methods and compositions for safe and effective treatment of erythema
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Methods and compositions for safe and effective treatment of erythema
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | AB | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | AB | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | |||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | AB | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | AB | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MIRVASO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005115395 | ⤷ Try it Free |
| Cyprus | 1114372 | ⤷ Try it Free |
| Australia | 2004242967 | ⤷ Try it Free |
| Japan | 4955543 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MIRVASO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1631293 | CR 2014 00031 | Denmark | ⤷ Try it Free | PRODUCT NAME: BRIMONIDIN OG ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER BRIMONIDIN TARTRAT; REG. NO/DATE: EU/1/13/904/001-003 20140221 |
| 1631293 | 132014902284452 | Italy | ⤷ Try it Free | PRODUCT NAME: BRIMONIDINA(MIRVASO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/904/001-002-003, 20140221 |
| 1631293 | C 2014 030 | Romania | ⤷ Try it Free | PRODUCT NAME: BRIMONIDINA SI SARURILE FARMACEUTICE ALE ACESTEIA5-BROMO-N-(4,5-DIHIDRO-1-H-IMIDAZOL-2-IL)QUINOXALIN-6-AMINA; NATIONAL AUTHORISATION NUMBER: EU/1/13/904; DATE OF NATIONAL AUTHORISATION: 20140221; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/904; DATE OF FIRST AUTHORISATION IN EEA: 20140221 |
| 1631293 | 14C0056 | France | ⤷ Try it Free | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
